Activities of Danilo Oscar LANCINI related to 2020/2076(INI)
Opinions (1)
OPINION on a New Industrial Strategy for Europe
Amendments (5)
Amendment 189 #
Draft opinion
Paragraph 6 a (new)
Paragraph 6 a (new)
6a. Calls on the Commission to develop a pharmaceutical strategy that will provide the right policy tools to foster the development of innovative medicines for the benefit of patients, ensure a stable and effective regulatory framework and take full advantage of the potential of the digital transformation of healthcare;
Amendment 194 #
Draft opinion
Paragraph 6 b (new)
Paragraph 6 b (new)
6b. Underlines the centrality of a well- functioning and competitive healthcare sector to ensure sustainable access to medicines for patients and guarantee the level of healthcare EU patients deserve; believes the Commission should facilitate the dialogue with the Member States and all the relevant stakeholders, in order to enable a comprehensive discussion and the development of multi-stakeholder solutions to issues concerning pharmaceutical sustainability and the introduction of new technologies into health systems; stresses that this platform for dialogue should take into account the different national approaches to pricing and reimbursement as well as healthcare investment and organisation;
Amendment 204 #
Draft opinion
Paragraph 6 c (new)
Paragraph 6 c (new)
6c. Calls the Commission and the Member States to put in place sustainable economic, regulatory and industrial policies to secure existing manufacturing operations in Europe and create a competitive framework for the industry to operate in a global environment;
Amendment 211 #
Draft opinion
Paragraph 6 d (new)
Paragraph 6 d (new)
6d. Calls for additional support to research and development programmes aimed at fostering the transition towards a safe and sustainable circular economy, promoting both innovative solutions and the scale-up of existing technologies in strategic sectors, including bio-based chemicals;
Amendment 214 #
Draft opinion
Paragraph 6 e (new)
Paragraph 6 e (new)
6e. Recalls the existing evidence highlighting the role of sustainable procurement practices in general, and specifically for pharmaceuticals, notably in ensuring security of supply and securing existing manufacturing investments in Europe; calls on the Commission to develop ad hoc EU Guidelines on procurement of medicines, under the current EU public procurement rules, looking at criteria beyond the lowest price only (MEAT criteria), such as ensuring long-term sustainability, competition, security of supply and stimulating investments in research and manufacturing;